How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

1,289 results for

Cough fracture

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

261. Perampanel (Fycompa)

disease studies resulting from post-surgical complications following injuries (hip fracture, femoral neck fracture, and cervical hematoma after a fall in a patient who had previously reported somnolence as an AE). There were 3 deaths due to malignancies 1 “primary chest malignancy”, 1 malignant lung neoplasm, and 1 metastatic adenocarcinoma. Neoplasms are discussed in more detail in Section 7.6 of Dr. Doi’s review. There was 1 death due to pancreatitis; cholelithiasis and pancreatitis are discussed

2012 FDA - Drug Approval Package

262. Teriflunomide

year old woman was diagnosed with respiratory failure on Day 533 of treatment with 7 mg/day. PFTs showed “mixed ventilatory deficiency”. Chest X-ray showed bilateral increased markings at the base. She had a dry cough, which improved with discontinuation of the treatment, and which recurred with resumption of treatment. 3) A 38 year old woman was diagnosed with ILD on Day 71 of treatment with 7 mg/day; she presented with difficulty breathing. She was a heavy smoker. X-ray showed reticular-nodular

2012 FDA - Drug Approval Package

263. Fluticasone furoate and Vilanterol (Breo Ellipta)

Trials 105 Table 51: On-treatment Bone Disorders and Fractures in 52-week Exacerbation Trials: 2871 and 2970 107 Table 52: Osteocalcin measurements: 871 108 Table 53: Serum CTX measurements: 871 108 Table 54: Fracture Data from Previous ICS/LABA Clinical Trials 109 Table 55: ICS-related AEs 1 in 24-week Lung Function Trials: 2206 and 2207 109 Table 56: ICS-related AEs 1 in 52-week Exacerbation Trials: 2871 and 2970 110 Table 57: Cardiac data in 24-week Lung Function Trials: 2206 and 2207 111 Table 58 (...) to clinic visits with spirometry) • Mucolytics at constant dosage • PRN oxygen for = 12 hours a day • Cardioselective beta-blockers (stable dose) and ophthalmic beta-blockers. • Antihistamines and nasal decongestants • OTC cough suppressants (for short term treatment =7 days) • Intranasal cromolyn or nedocromil • Intranasal, ophthalmic and topical corticosteroids • Antibiotics that are not strong inhibitors of cytochrome P450 3A4 for short term treatment ( =14 days) of acute non-respiratory tract

2012 FDA - Drug Approval Package

264. Eliglustat Tartrate, Miglistat, Imiglucerase, Velaglucerase or a Combination of these for the Treatment of Gaucher Disease A Review of Clinical Effectiveness and Safety

in preventing some of the skeletal manifestations of type 1 Gaucher disease. They noted that weak quantitative evidence suggested that ERT appears to have a positive effect on bone pain, bone crises, and bone fractures. However, they stated the results should be interpreted with caution as the available data also suggested the possibility that ERT may exacerbate depletion in bone density. Overall, the authors concluded that all studies were suggested that ERT was beneficial in patients with Gaucher disease (...) reported for patients treated with miglustat. Diarrhea (72%), tremor (38%), abdominal pain (34%), and cough (34%) were the most commonly reported adverse events. At least one serious adverse event was reported for six patients (21%) treated with miglustat. Table 5: Summary of systemic disease endpoints from Schiffmann et al, 2007 12 Endpoints Time point Miglustat No miglustat n Mean (95% CI) n Mean (95% CI) Forced vital capacity (% actual / predicted) Baseline 9 75.1 (62.0, 88.2) 6 79.5 (61.3, 97.6

2012 Canadian Agency for Drugs and Technologies in Health - Rapid Review

265. Prognostic Factors of a Favorable Outcome Following an Exercise Program for Soldiers With Low Back Pain

analog scale graduated 0-100 Pain in lying position [ Time Frame: Baseline ] Visual analog scale graduated 0-100 Pain in standing position [ Time Frame: Baseline ] Visual analog scale graduated 0-100 Pain during walking [ Time Frame: Baseline ] Visual analog scale graduated 0-100 Pain when coughing or sneezing [ Time Frame: Baseline ] Visual analog scale graduated 0-100 Mean pain perceived in the last 48 hours [ Time Frame: Baseline ] Visual analog scale graduated 0-10 Worst pain perceived (...) conditions (e.g. tumor, fracture, rheumatoid arthritis, osteoporosis) unavailability to participate in the 6-week exercise program Contacts and Locations Go to Information from the National Library of Medicine To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor. Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03464877 Locations Layout table for location information Canada, Quebec

2018 Clinical Trials

266. Treatment of Sarcoma Lung Metastases with Stereotactic Body Radiotherapy Full Text available with Trip Pro

was 14.2 months (range 1.6-98.6 months). Overall survival was 82% at two years and 50% at five years. Of 117 metastatic nodules treated, six nodules showed failure of treatment (95% control rate). Twenty patients (27%) developed new metastatic lesions and underwent further SBRT. The side effects of SBRT included transient radiation pneumonitis (n=6), cough (n=2), rib fracture (n=1), chronic pain (n=1), dermatitis (n=1), and dyspnea (n=1).Stereotactic body radiotherapy is an effective and safe treatment

2018 Sarcoma

267. A 56-Year-Old Woman With Multiple Pulmonary Cysts and Severe Chest Pain. (Abstract)

A 56-Year-Old Woman With Multiple Pulmonary Cysts and Severe Chest Pain. A 56-year-old woman presented to our hospital with a 4-month history of worsening chest pain. She denied having any respiratory symptoms, such as dyspnea, sputum, cough, or hemoptysis, or any history of smoking or exposure to dusts. One year previously she had a vertebral fracture. There was no specific family history, including pulmonary or autoimmune diseases. Chest CT performed 3 years earlier showed multiple thin

2018 Chest

268. Effect of the Neck Extension on Blind Intubation Via Ambu® AuraGain™

will be intubated using a direct laryngoscopy. The primary outcome of this study is the success rate of blind intubation within a first attempt. Secondary outcomes included overall success rate of blind intubation within a maximum of two attempts, time for blind intubation, the incidence of postoperative hoarseness, cough, and sore throat, and any obvious complications related to airway management such as bleeding, airway trauma, dental fracture, aspiration, or bronchospasm. Condition or disease Intervention (...) intubation within a maximum of two attempts Time for blind intubation [ Time Frame: In a maximum of two attempts for blind intubation, an average of 60 seconds ] Time between insertion of an endotracheal tube within the laryngeal mask and detection of end-tidal CO2 from the tube Postoperative hoarseness [ Time Frame: 24 hours after extubation ] The incidence of postoperative hoarseness Postoperative cough [ Time Frame: 24 hours after extubation ] The incidence of postoperative cough Postoperative sore

2018 Clinical Trials

269. Study of Fruquintinib (HMPL-013) in High Risk Patients With Advanced NSCLC

Patients who have a history of arterial thrombosis or deep venous thrombosis within 6 months prior to administration of the study drug; history or evidence of thrombosis or bleeding tendency regardless of the severity within 2 months; history of hemoptysis (i.e. coughing blood in bright red color at least 2.5ml or 1/2 teaspoon) within 2 weeks; history of liver hemangioma > 3 cm Patients who have a history of stroke and/or transient ischemic attack within 12 months prior to administration of the study (...) drug Patients with skin wound, surgical site, wound site, severe mucosal ulcer or fracture without complete healing Pregnant or lactating women, or women of child bearing potential with positive pregnancy test result before the first dose; Patients with child bearing potential who or whose sexual partners are not willing to take contraceptive measures Patients with any clinical or laboratory abnormalities unsuitable for participating in this clinical trial according to the investigator's judgment

2018 Clinical Trials

270. Osimertinib as First-line Therapy for Patients With Late-stage Lung Cancer

or exposure to high risk factor for the disease; pulmonary function tests: forced expiratory volume in one second(FEV1)<80 %predicted, FEV1/ FVC<70%;With/without symptoms: shortness of breath, chronic cough, sputum production] ; 2)active interstitial lung disease(ILD)[ pulmonary function tests: FEV1/ FVC<70%, FEV1<80 %predicted, diffusing capacity of the lung for carbon monoxide (DLCO)< 40%;high-resolution computed tomography(HRCT) confirmed diffuse pulmonary interstitial lesions]. Any diseases, metabolic (...) requiring medical treatment; hepatic, renal or metabolic diseases. Active infection of human immunodeficiency virus (HIV). Patients with unhealing wound ,active peptic ulcer or bone fracture. Females who are 1)pregnant;2)breastfeeding;3)of reproductive potential planning to become pregnant; Males and females who are not using an effective method of birth control. History of allergic reactions attributed to compounds, or any of its excipients, of similar chemical or biologic composition to Osimertinib

2018 Clinical Trials

271. Gemcitabine and Cisplatin With/Without Anlotinib in Advanced Nasopharyngeal Carcinoma

immunosupressive drugs (i.e., Corticosteroids, cyclophosphamide, azathioprine, methotrexate, thalidomide or TNF-α) Symptomatic CNS metastasis (i.e. encephaledema, hormone intervention, or brain metastasis progression) Patients currently have bleeding tendency, including but not limited to gastrointestinal bleeding, nasal bleeding, hemoptysis, and persistent bleeding or coagulopathy; Hemoptysis (defined as coughing out or spitting out ≥ 1 teaspoon of blood or small blood clots or hemoptysis without sputum (...) ; Chronic Obstructive Pulmonary Disease (COPD) or other respiratory diseases requiring hospitalization within 28 days before randomization; Abdominal fistula, gastrointestinal perforation, intra-abdominal abscess, or acute gastrointestinal bleeding within 24 weeks before randomization; Esophageal and gastric varices, unhealed ulcers, unhealed wounds or fracture within 24 weeks before randomization; Pulmonary infections and/or acute bacterial or fungal infections requiring intravenous antibiotic therapy

2018 Clinical Trials

272. Reliability of the Doha Agreement Classification of Groin Pain

testing), "Pubic-related" (local tenderness of the pubic symphysis and the immediately adjacent bone), "Iliopsoas-related" (iliopsoas tenderness AND more likely with pain on resisted hip flexion AND/OR pain on stretching of the iliopsoas), "Inguinal-related" (pain location in the inguinal canal region AND tenderness of the inguinal canal. No palpable inguinal hernia. More likely if the pain is aggravated with resistance testing of the abdominal muscles OR on Valsalva/cough/sneeze), or "Hip-related (...) of the examiners for the same complaints. fractures or acute injuries with severe pain were it would be unethical to examine the athlete twice. Contacts and Locations Go to Information from the National Library of Medicine To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor. Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03590145 Contacts Layout table for location contacts Contact

2018 Clinical Trials

273. A Study of Injection HB002.1T in Subjects With Solid Tumor

pressure or diastolic blood pressure ≥90mmHg after antihypertensive treatment (one antihypertensive drug is allowed in the baseline period, and the compound preparation is recognized as two); The subject has an active infection or during the screening period, the unexplained fever occurs before the first dose > 38.5 °C; Those who have had hemoptysis within 4 weeks before screening (defined as coughing with ≥1 teaspoon of blood), but do not rule out cough only with sputum or small blood clot; Subjects (...) 4 weeks prior to screening; History of abdominal hernia, gastrointestinal perforation abscess or acute bleeding in the first 6 months prior to screening; Esophageal varices, unhealed wounds or fractures within 6 months prior to screening; Dominant jaundice and/or caused by abnormal liver function Subjects who are in use of warfarin, heparin aspirin (>325 mg/day) or other drugs known to inhibit platelet function within 10 days prior to the first study treatment; Subjects receiving dipyridamole

2018 Clinical Trials

274. Changes in corneal thickness in patients with high-altitude pulmonary edema after systemic oxygen therapy Full Text available with Trip Pro

Changes in corneal thickness in patients with high-altitude pulmonary edema after systemic oxygen therapy High-altitude pulmonary edema (HAPO) is an acute medical emergency occurring typically in lowlanders, who ascend rapidly to heights of 3000 m or more. It presents with marked dyspnea on exertion, fatigue with minimal-to-moderate effort, prolonged recovery time, and dry cough with manifestations of cyanosis, tachycardia, tachypnea, and temperature which generally does not increase beyond (...) and controls were patients admitted in hospital for low back pain, fractures, and minor surgical procedures. Central corneal thickness (CCT) was measured with an ultrasound pachymeter on day 1 of hospitalization and every day of hospital stay. Systemic oxygen concentration was also measured daily.There was no statistically significant difference in corneal thickness between two groups at the onset of illness, but a significant decrease in CCT was found in both right and left eyes in HAPO cases when oxygen

2018 Indian journal of ophthalmology

275. A Natural History Study In Chinese Male Patients With Duchenne Muscular Dystrophy

: Change from baseline, 12, 24, 30 Months ] Change from Baseline in pulmonary function tests - Maximum Expiratory Pressure [ Time Frame: Change from baseline, 12, 24, 30 Months ] Change from Baseline in pulmonary function tests - Peak cough flow [ Time Frame: Change from baseline, 12, 24, 30 Months ] Change from Baseline in range of motion (ROM) at bilateral ankles and elbows [ Time Frame: Change from baseline, 6, 12, 18, 24, 30 Months ] Change from Baseline in left ventricular ejection fraction (LVEF (...) in these subjects is considered inappropriate in the opinion of Investigators. Exclusion Criteria: Any injury which may impact functional testing. Previous injuries must be fully healed prior to consenting. Prior lower limb fractures must be fully healed and at least 3 months from injury date. Presence or history of other musculoskeletal or neurologic disease or somatic disorder not related to DMD including pulmonary, cardiac, and cognitive diseases. Subjects >=4 years old who have not completed the recommended

2018 Clinical Trials

276. Operative Versus Non-Operative Treatment of Clavicle Fracture in PolyTrauma

fractures. Chest injuries can restrict patients' ability to breathe, cough, stand, walk and leave the hospital. Although it is unusual that chest injuries can be improved with surgery, patients with clavicle fractures and chest injuries might recover faster if the clavicle fractures were repaired. Patients are being asked to take part in the study they have sustained a clavicle fracture associated with a chest injury with or without any other injury to the abdomen, or arms or legs. The aim of this study (...) Operative Versus Non-Operative Treatment of Clavicle Fracture in PolyTrauma Operative Versus Non-Operative Treatment of Clavicle Fracture in PolyTrauma - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more

2010 Clinical Trials

277. Multiple Lumbar Pedicle Fractures in Osteopetrosis: A Case Report. (Abstract)

in the cervical and lumbar spine, and pedicle fractures have been reported in the cervical spine. We report the case of a patient with autosomal dominant osteopetrosis with multiple lumbar pedicle fractures. To the best of our knowledge, there have been no previous reports of multiple lumbar pedicle fractures in osteopetrosis.A 73-year-old woman, with a known history of osteopetrosis, presented with acute nonradiating low back pain following a bout of coughing. The lower limb neurology and bladder and bowel (...) Multiple Lumbar Pedicle Fractures in Osteopetrosis: A Case Report. Single case report.To report the observation of multiple lumbar pedicle fractures in a patient with osteopetrosis.Osteopetrosis is characterized by osteoclast dysfunction, impaired bone resorption, and poor bone remodeling. As a result, the bone is brittle but hard and is referred to as "marble bone disease." Although long bone fractures are relatively common, fractures of the spine are rare. Spondylolysis has been reported

2010 Spine

278. Position Statement on Percutaneous Vertebral Augmentation: A Consensus Statement Developed by the Society of Interventional Radiology (SIR), American Association of Neurological Surgeons (AANS) and the Congress of Neurological Surgeons (CNS), American Col

, PinaC.Sanelli,MD,MPH,MarcS.Schwartzberg,MD,DavidSeidenwurm,MD,SeanM.Tutton,MD, Gregg H. Zoarski, MD, Michael D. Kuo, MD, Steven C. Rose, MD, and John F. Cardella, MD ABBREVIATIONS ADR= adverse drug reaction, DVT= deep vein thrombosis, FREE= Fracture Reduction Evaluation trial, INVEST= Investigational Vertebroplasty Safety and Ef?cacy Trial, NRS= numeric rating scale, PVA = percutaneous vertebroplasty, RDQ = Roland–Morris disability questionnaire, SF-36 = Short Form–36, VAS = visual analog scale, VCF (...) = vertebral compression fracture From the California Center for Neurointerventional Surgery (J.D.B.), La Jolla; Radiological Associates of Sacramento (D.S.), Sacramento; Department of Radiology(M.D.K.),UniversityofCalifornia,LosAngeles,MedicalSchool,Los Angeles; Department of Radiology (S.C.R.), University of California, San Diego, Medical Center, San Diego, California; Department of Radiology (M.E.J.), University of Virginia Health System, Charlottesville, Virginia; Divi- sion of Neurointerventional

2014 Society of Interventional Radiology

279. Diagnosis and Management of Bronchiolitis Obliterans Syndrome: An Official ATS/ERS/ISHLT Clinical Practice Guideline

to be clinically significant (conditional recommendation, very low quality of evidence). Values and preferences: this recommendation places a high value on preventing a life-threatening complication of lung transplantation and a lower value on avoiding short-term side-effects. Remarks: we consider Grade A1 acute cellular rejection to be clinically significant if it is associated with clinical findings, such as symptoms (e.g. dyspnoea, fatigue or new-onset cough) or objective measurements (e.g. decline in FEV1 (...) gain ii) Abdominal distention iii) Hyperinflation of native lung in SLT for emphysema iv) Pleural complications 1. Pneumothorax 2. Pleural effusion 3. Pleural fibrosis 4. Bronchopleural fistula c) Impaired graft inflation i) Pain (vertebral fracture, fracture of ribs and/or sternum) ii) Ventilatory compromise 1. Diaphragmatic dysfunction or paralysis 2. Chest wall myopathy iii) Other (cerebrovascular accident, Parkinson’s disease, etc.) d) Drug reaction (e.g. sirolimus, everolimus and amiodarone) e

2014 American Thoracic Society

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>